GLP-1 receptor agonists have evolved from twice-daily injections to once-weekly and oral options, becoming the preferred first injectable diabetes therapy with proven cardiovascular benefits.
Preferred first injectable over insulinGuidelines now recommend GLP-1 RAs before insulin for type 2 diabetes, based on comparable glucose lowering plus weight loss and cardiovascular protection without hypoglycemia risk
What the researchers found
This comprehensive review covers the entire GLP-1 receptor agonist class for type 2 diabetes, documenting their evolution from twice-daily exenatide (2005) to once-weekly and oral formulations. Key conclusions: GLP-1 RAs reduce HbA1c and body weight without intrinsic hypoglycemia risk, are now recommended as the preferred first injectable therapy before insulin, and several cardiovascular outcome trials have shown they prevent heart attacks, strokes, and associated mortality in patients with atherosclerotic disease. Semaglutide emerged as the most effective for both glucose lowering and weight loss. Novel indications being explored include type 1 diabetes, neurodegenerative diseases, and psoriasis.
Why it matters
This review captures a pivotal moment in GLP-1 RA history — the class had just been elevated in treatment guidelines to preferred first injectable therapy over insulin, cardiovascular benefits were confirmed across multiple large trials, and oral semaglutide had just arrived. It provides the authoritative summary of how GLP-1 RAs transformed diabetes treatment within 15 years of their introduction.
The numbers in context
First approved 2005 · Dosing ranges: twice daily to once weekly to daily oral · CV outcome trials from 2016 onward · Semaglutide: most effective for HbA1c + weight
How the study worked
Narrative review summarizing clinical trial data, mechanisms of action, pharmacological development, cardiovascular outcome studies, and treatment guidelines for the GLP-1 receptor agonist class.
Who was studied
Adults with type 2 diabetes (review of clinical trial populations)
What this study cannot tell us
This is a narrative review, not a systematic review or meta-analysis, so it does not use formal methodology for evidence synthesis. Published in early 2021, it predates tirzepatide approval and the explosion of GLP-1 use for obesity as a primary indication.
How to read the evidence
This is a comprehensive narrative review published in a respected journal by leading GLP-1 researchers (including Michael Nauck, one of the pioneers of incretin research). It synthesizes evidence from multiple large randomized trials including cardiovascular outcome studies, representing a strong evidence base.
When this study was published
Published in 2021, this review predates tirzepatide approval and the massive expansion of GLP-1 use for obesity. The core pharmacology and cardiovascular data remain accurate, but the therapeutic landscape has expanded significantly since publication.
The bigger picture
This review documents the moment GLP-1 RAs graduated from 'another diabetes drug' to a transformative drug class. The cardiovascular protection findings from 2016 onward fundamentally changed treatment guidelines, and the arrival of oral semaglutide broke the injection barrier. Just a few years later, the class would expand further into obesity treatment, making this review a snapshot of the field right before its next major leap.
Questions still open
- Which specific patient subgroups benefit most from GLP-1 RAs, and can pharmacogenomics help identify the best responders?
- Will GLP-1 RAs prove effective for neurodegenerative diseases and other non-diabetes indications being explored?
- How should clinicians choose between GLP-1 RAs and SGLT-2 inhibitors based on individual patient cardiovascular risk profiles?
Common questions
What's the difference between short-acting and long-acting GLP-1 receptor agonists?
Why are GLP-1 RAs now recommended before insulin for type 2 diabetes?
Read the original research
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
Molecular metabolism, 46, 101102
Citation
Nauck, Michael A; Quast, Daniel R; Wefers, Jakob; Meier, Juris J. (2021). GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.. Molecular metabolism, 46, 101102. https://doi.org/10.1016/j.molmet.2020.101102